[go: up one dir, main page]

EP1446014A4 - INTRODUCTION OF THE WLDS GENE FOR THE PREVENTION OF AXONAL DEGENERATION IN NEUROLOGICAL DISEASES - Google Patents

INTRODUCTION OF THE WLDS GENE FOR THE PREVENTION OF AXONAL DEGENERATION IN NEUROLOGICAL DISEASES

Info

Publication number
EP1446014A4
EP1446014A4 EP02800391A EP02800391A EP1446014A4 EP 1446014 A4 EP1446014 A4 EP 1446014A4 EP 02800391 A EP02800391 A EP 02800391A EP 02800391 A EP02800391 A EP 02800391A EP 1446014 A4 EP1446014 A4 EP 1446014A4
Authority
EP
European Patent Office
Prior art keywords
wlds
gene
introduction
prevention
neurological diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02800391A
Other languages
German (de)
French (fr)
Other versions
EP1446014A2 (en
Inventor
Jonathan D Glass
Mark M Rich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emory University
Original Assignee
Emory University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emory University filed Critical Emory University
Publication of EP1446014A2 publication Critical patent/EP1446014A2/en
Publication of EP1446014A4 publication Critical patent/EP1446014A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP02800391A 2001-10-01 2002-10-01 INTRODUCTION OF THE WLDS GENE FOR THE PREVENTION OF AXONAL DEGENERATION IN NEUROLOGICAL DISEASES Withdrawn EP1446014A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32635401P 2001-10-01 2001-10-01
US326354P 2001-10-01
PCT/US2002/031078 WO2003029414A2 (en) 2001-10-01 2002-10-01 INTRODUCTION OF THE WLDs GENE FOR PREVENTION OF AXONAL DEGENERATION IN NEUROLOGICAL DISEASES

Publications (2)

Publication Number Publication Date
EP1446014A2 EP1446014A2 (en) 2004-08-18
EP1446014A4 true EP1446014A4 (en) 2004-12-08

Family

ID=23271854

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02800391A Withdrawn EP1446014A4 (en) 2001-10-01 2002-10-01 INTRODUCTION OF THE WLDS GENE FOR THE PREVENTION OF AXONAL DEGENERATION IN NEUROLOGICAL DISEASES

Country Status (3)

Country Link
EP (1) EP1446014A4 (en)
CA (1) CA2462632A1 (en)
WO (1) WO2003029414A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1553964A4 (en) * 2002-09-25 2009-08-12 Georgia Tech Res Inst Ketoamide inhibitors in chronic nerve disease
GB201006961D0 (en) * 2010-04-27 2010-06-09 Babraham Inst NMN modulator
US11597917B2 (en) * 2017-07-06 2023-03-07 The Medical College Of Wisconsin, Inc. In vitro and in vivo enrichment strategy targeting lymphocytes derived from vector transduced HSCs for therapy of disorders
SG11202010645VA (en) 2018-04-27 2020-11-27 Medical College Wisconsin Inc Use of lentivector-transduced t-rapa cells for amelioration of lysosomal storage disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001064907A2 (en) * 2000-03-02 2001-09-07 Incyte Genomics, Inc. Lipid metabolism enzymes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001064907A2 (en) * 2000-03-02 2001-09-07 Incyte Genomics, Inc. Lipid metabolism enzymes

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CONFORTI L ET AL: "A Ufd2/D4Cole1e chimeric protein and overexpression of Rbp7 in the slow Wallerian degeneration (WldS) mouse", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 97, no. 21, 10 October 2000 (2000-10-10), pages 11377 - 11382, XP002953257, ISSN: 0027-8424 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 2001, COLEMAN M P ET AL: "Protecting axons: The molecular basis of slow Wallerian degeneration", XP002299951, Database accession no. PREV200200038753 *
DATABASE GENBANK 2 October 2000 (2000-10-02), CONFORTI; ET AL: "Mus musculus UFD2/D4COLE1E fusion protein mRNA", XP002953260, retrieved from GENBANK Database accession no. AF260924 *
FERNANDO S ET AL: "Characterization of the human homologue of a candidate gene for slow Wallerian degeneration", AMERICAN JOURNAL OF HUMAN GENETICS, AMERICAN SOCIETY OF HUMAN GENETICS, CHICAGO, IL, US, vol. 67, no. SUPPLEMENT 2, October 2000 (2000-10-01), pages 178, XP002953261, ISSN: 0002-9297 *
SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 27, no. 2, 2001, 31ST ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE; SAN DIEGO, CALIFORNIA, USA; NOVEMBER 10-15, 2001, pages 2623, ISSN: 0190-5295 *
WANG M-S ET AL: "Pathogenesis of axonal degeneration: parallels between Wallerian degeneration and vincristine neuropathy", JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, NEW YORK, NY, US, vol. 59, no. 7, July 2000 (2000-07-01), pages 599 - 606, XP002953258, ISSN: 0022-3069 *
WANG M-S ET AL: "The gene for low Wallerian degeneration (WldS) is also protective against vincristine neuropathy", NEUROBIOLOGY OF DISEASE, BLACKWELL SCIENTIFIC PUBLICATIONS, OXFORD, GB, vol. 8, 20 December 2000 (2000-12-20), pages 155 - 161, XP002953259, ISSN: 0969-9961 *

Also Published As

Publication number Publication date
WO2003029414A3 (en) 2003-12-18
CA2462632A1 (en) 2003-04-10
EP1446014A2 (en) 2004-08-18
WO2003029414A2 (en) 2003-04-10

Similar Documents

Publication Publication Date Title
AU2002252373A1 (en) Methods and compositions for the treatment and/or diagnosis of neurological diseases and disorders
AU2003253014A8 (en) Method for the diagnosis and differential diagnosis of neurological diseases
WO2003033720A8 (en) Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
IL161327A0 (en) Methods for treating ocular neovascular diseases
ZA200308316B (en) Fusion molecules and methods for treatment of immune diseases
AU2002331777A1 (en) Arrays comprising pre-labeled biological molecules and methods for making and using these arrays
MXPA03007983A (en) Process for the preparation of middle distillates.
AU2002310187A1 (en) Inhibitors of protein kinase for the treatment of disease
AU8187701A (en) Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders
EP1680145A4 (en) Methods and compositions for the treatment of neurological disease
AU2002353777A1 (en) Saliva-based methods for preventing and assessing the risk of diseases
AU3840802A (en) Methods and compositions for the treatment of diseases of the eye
AU2002353310A8 (en) Method for the preparation of nucleic acids
AU2002360245A1 (en) Plasticized hydrophilic glasses for improved stabilization of biological agents
IL162511A (en) Method for determining the biological activity of defibrotide
AU2002252713A1 (en) Method of delivering liquid through cerebral spinal pathway
AU2002343537A8 (en) Stiffened surface micromachined structures and process for fabricating the same
EP1446014A4 (en) INTRODUCTION OF THE WLDS GENE FOR THE PREVENTION OF AXONAL DEGENERATION IN NEUROLOGICAL DISEASES
AU2002362115A1 (en) Composition and methods for treatment of neurological disorders
AU2002319053A1 (en) Egg concentrate product and methods for making and utilizing the same
AU3004000A (en) Methods for the treatment of apolipoprotein e related diseases
AU2002258798A1 (en) Methods for the treatment of hepatic disorders
AU2002239531A1 (en) Differential gene expression in specific regions of the brain in neurodegenerative diseases
ID28738A (en) COMPOSITE SHEETS WHICH CAN BE SHOULD BE LIMITED FOR HEALTH OBJECTIVES OF THE BODY LIQUID ABSORER AND THE PROCESS OF MAKING IT
GB2370039B (en) Producing protein arrays and fusion protein for use therein

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040424

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20041027

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61P 25/00 B

Ipc: 7A 61K 31/713 B

Ipc: 7A 61K 38/17 B

Ipc: 7C 12Q 1/68 B

Ipc: 7C 12N 15/62 B

Ipc: 7C 07K 19/00 B

Ipc: 7C 07K 14/47 B

Ipc: 7C 12N 15/12 B

Ipc: 7C 12N 15/85 B

Ipc: 7C 12N 15/74 B

Ipc: 7C 12N 15/70 B

Ipc: 7C 12N 15/63 B

Ipc: 7C 12N 15/09 B

Ipc: 7C 12N 15/00 B

Ipc: 7A 61K 31/70 B

Ipc: 7A 61K 48/00 B

Ipc: 7A 01N 43/04 B

Ipc: 7A 01N 65/00 B

Ipc: 7A 01N 63/00 A

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060503